Full-Time

Injection Molding Maintenance Technician 2

Updated on 9/11/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

Compensation Overview

$27.90 - $44.60/hr

Hunt Valley, Cockeysville, MD, USA

In Person

Third shift, Monday through Friday, 10:00 p.m. to 6:30 a.m.

Bachelor's

Category
General Maintenance & Repair (1)
Required Skills
Welding
GMP
AutoCAD
SAP Products
Word/Pages/Docs
Injection Molding
Robotics
Plumbing
SolidWorks
Excel/Numbers/Sheets

Get referred to Becton Dickinson

See people who can refer or advise you

Requirements
  • A High School Diploma or GED and 2 years of relevant experience.
  • Relevant experience as an Electrical or Electronics Technician, Electromechanical Technician, Mechanical Engineering Technician, Industrial Programmer, Electrician, Machine Builder or Repairer, Machinist, Refrigeration Mechanic, or Welding Repairer.
  • Mechanical, pneumatic, and electrical skills to analyze, troubleshoot, and repair complex equipment and machinery.
  • Ability to read electrical and pneumatic schematics.
  • Ability to read and interpret technical manuals, blueprints, diagrams, and equipment specifications.
  • Knowledge of trades mathematics, calibration techniques, and precision measuring instruments.
  • Ability to use a personal computer, including Microsoft Excel and Microsoft Word.
  • Ability to use a multimeter.
  • Knowledge of sensor technology, basic plumbing for fluid and pneumatic systems, power transmission, and basic machining.
  • Ability to troubleshoot electrical circuits from low-level signals up to 480 VAC.
  • Ability to follow established procedures according to Good Manufacturing Practices.
  • Ability to work overtime as required to meet business requirements.
Responsibilities
  • Perform routine setup, operation, minor and major routine maintenance, preventive maintenance, and troubleshooting of highly complex or automated manufacturing equipment.
  • Control and adjust machine settings and manage production, quality, downtime, and waste levels associated with machine operation.
  • Perform mechanical, pneumatic, and electrical maintenance, repairs, adjustments, inspections, and monitoring of production and facilities-related equipment and machinery.
  • Plan, perform, make decisions, troubleshoot, and solve problems while completing maintenance tasks.
  • Prioritize daily work assignments to meet production needs and department goals.
  • Schedule preventive maintenance and complete work orders and assigned tasks.
  • Support equipment installation and removal and perform corrective maintenance.
  • Monitor production lines and proactively evaluate equipment performance for repairs and continuous improvement.
  • Complete equipment changeovers and operator-level preventive maintenance.
  • Assist with root-cause analysis for process or product exceptions.
  • Use prescribed gauges, jigs, and fixtures to measure close tolerances.
  • Maintain accurate quality, safety, and maintenance documentation.
  • Organize, execute, and direct improvement projects to increase equipment utilization.
  • Identify, troubleshoot, and resolve complex issues involving machine performance or product quality.
  • Advise on preventive-maintenance task-list content and execution frequency.
  • Assist with installation, debugging, and startup of new or modified production equipment.
  • Work with external contractors and vendors as needed.
  • Follow BD housekeeping and safety policies and procedures.
Desired Qualifications
  • Experience troubleshooting industrial control systems, including instrumentation, ladder logic, relay logic, variable-frequency drives, and servo systems.
  • Knowledge and proficiency in programmable logic controller operations, robotics, and vision systems.
  • Mechanical design experience with AutoCAD, SolidWorks, or similar tools.
  • Experience with the SAP maintenance module or an equivalent computerized maintenance system.
  • Basic skills using a mill, lathe, welding equipment, and bearing press.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
  • Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
  • Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.

What critics are saying

  • FDA classified BD’s intraosseous recall Class I on August 17, 2026.
  • The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
  • Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.

What makes Becton Dickinson unique

  • BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
  • BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
  • BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
Yahoo Finance
Aug 18th, 2026
Wall Street analysts give Becton, Dickinson a 'moderate buy' rating despite 12% earnings decline forecast

Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".

PR Newswire
Aug 17th, 2026
BD names Gary Sorsher chief quality officer as Jeff Silvestri retires after 25 years

BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.

MedTech Dive
Aug 13th, 2026
BD fully enrolls trial of resorbable mesh for hernia prevention.

BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."

Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.